Navigation Links
CSL Behring Reaches Primary Endpoint in Clinical Study of C1-INH for Treatment of Hereditary Angioedema
Date:11/26/2007

KING OF PRUSSIA, Pa., Nov. 26 /PRNewswire/ -- CSL Behring announced today that it has reached the primary endpoint of a Phase III clinical trial of human pasteurized C1-inhibitor (C1-INH) concentrate to treat patients with hereditary angioedema (HAE), a rare genetic disorder that can lead to painful and sometimes life-threatening attacks of edema (swelling) of the face, airway, abdomen, and extremities.

The results from the Phase III, double blind, placebo-controlled trial I.M.P.A.C.T. (International Multi-centre Prospective Angioedema C1-inhibitor Trial), showed that patients treated with 20 U/kg b.w. C1-INH experienced a highly significant reduction in time to onset of relief of symptoms of HAE attacks compared to placebo (p= 0.003, one sided). In addition, all secondary endpoints of the trial have shown significant positive results, e.g. worsening of symptoms (p= 0.001, one sided).

"The results of this trial can immediately impact the lives of the thousands of HAE patients around the world who live with the burden of acute HAE attacks without approved treatment," said Timothy Craig, M.D., professor of medicine and pediatrics, Penn State Hershey Medical Center, USA, coordinating investigator of the I.M.P.A.C.T. trial.

I.M.P.A.C.T. is a multi-center, prospective clinical trial conducted globally in more than 45 centers in 15 countries, enrolling 125 patients, and is the largest trial ever conducted in HAE. For the first time, a dose comparison study was conducted for a human C1-INH comparing 20U/ kg b.w. and 10U/ kg b.w. in a randomized, placebo-controlled, double-blind study design. The results will be submitted in the near future to the United States Food and Drug Administration, Health Canada and European Health Authorities in support of applications to license C1-INH concentrate for the treatment of acute attacks of HAE in the U.S., Canada, and Europe. CSL Behring has manufactured and provided C1-INH concentrate to HAE patients for o
'/>"/>

SOURCE CSL Behring
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Enrollment Reaches 110 Patients in Investigator Initiated, Randomized Trial of OrbusNeichs Genous(TM) Bio-Engineered R Stent(TM)
2. Arizona Heart Hospital Reaches Settlement Regarding Clinical Research Matter
3. Genzyme Announces Second Pivotal Mozobil Trial Meets Primary Endpoint
4. New Research May Lead to Earlier Diagnosis and Treatment of Primary Biliary Cirrhosis in Families
5. ERBITUX(R) Meets Primary Endpoint of Increasing Survival in Phase III Lung Cancer Study
6. Anesiva Announces Pivotal Phase 3 Trial of Zingo(TM) Meets Primary Endpoint and Significantly Reduces Venous Access Pain in Adults
7. Tezampanel Meets Primary Endpoint in Phase IIb Clinical Trial in Acute Migraine Headache
8. ADVENTRX Meets Primary Endpoint in ANX-530 Marketing-Enabling Clinical Study
9. Phase III Clinical Trial in Newly Diagnosed Multiple Myeloma Stopped Early Due to Highly Significant Efficacy Advantage of VELCADE(R) (Bortezomib) for Injection Based Therapy Across All Endpoints
10. A Phase II, Randomized, Double Blind, Placebo-Controlled Dose-Escalating Study, Meets the Clinical Endpoints of MTR106 Tablets During the Treatment of Acute Migraine Attacks Without Aura in Females
11. Cethromycin Achieves All Endpoints in Second Pivotal Phase III Trial for Treatment of Pneumonia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/4/2015)... 4, 2015   Mayo Clinic and ... the next generation of wearable biosensors designed to fight ... this technology will be game-changer. These patch biosensors may ... James Levine, M.D., Ph.D. , a Mayo Clinic ... and can be integrated into the care people receive." ...
(Date:3/4/2015)... , March 4, 2015  Results of the ... Consecutive Cases Using MarginProbe for Intra-Operative Positive Margin Detection ... session at the 32 nd Annual Miami Breast ... conducted by Moshe Papa , MD, FACS, Professor ... Tel Aviv University, reports an analysis of MarginProbe,s efficiency ...
(Date:3/4/2015)... 4, 2015  Bayer HealthCare today announced that ... accepted the company,s Biologics License Application (BLA) for ... is seeking FDA approval of the investigational compound, ... hemophilia A in children and adults. ... therapies to hemophilia A patients who need them," ...
Breaking Medicine Technology:Mayo Clinic and Gentag, Inc. Announce Agreement To Develop Wireless Sensors for Treatment of Obesity and Diabetes 2Mayo Clinic and Gentag, Inc. Announce Agreement To Develop Wireless Sensors for Treatment of Obesity and Diabetes 3New Study Shows Breast Re-excision Rates Significantly Reduced in 100 Consecutive Cases 2FDA Accepts Bayer's Biologics License Application for Investigational Treatment Option in Hemophilia A 2FDA Accepts Bayer's Biologics License Application for Investigational Treatment Option in Hemophilia A 3
... Laboratories, L.C. and Intercell AG (VSE; "ICLL") ... of Romark,s antiviral drug, nitazoxanide, in combination ... (HCV) vaccine, IC41, during the first half ... (Logo: http://www.newscom.com/cgi-bin/prnh/20100201/FL47022LOGO) Intercell,s vaccine ...
... Oct. 21 IDEV Technologies, Incorporated (IDEV), an innovative ... medical technologies, today announced another step in the implementation ... treating patients with peripheral vascular disease with the addition ... The initial uses of the newly introduced 180mm and ...
Cached Medicine Technology:Romark and Intercell Join Forces in Combining Therapies Against Hepatitis C 2Romark and Intercell Join Forces in Combining Therapies Against Hepatitis C 3Romark and Intercell Join Forces in Combining Therapies Against Hepatitis C 4Romark and Intercell Join Forces in Combining Therapies Against Hepatitis C 5IDEV Technologies Launches Additional Products in Europe 2
(Date:3/4/2015)... 04, 2015 FDA’s New Inspection Approach:, ... Webinar**, March 24, 2015 — 1:30 p.m. – 3:00 ... know within four hours of an inspection whether a ... on their “good” list, they’ll merely ask for reassurance ... is on the “bad” list, the manufacturer must get ...
(Date:3/4/2015)... the growing influence of movies, television, video games and the ... combined with the increasingly frantic lifestyle of modern parents, it ... with what kids are into these days. It seems that ... basis. , The same is also true for drugs and ... discreetly talk about them, are constantly changing. These tips put ...
(Date:3/4/2015)... (PRWEB) March 04, 2015 Vancouver ... recently received two awards in the prestigious Vancouver ... on February 27, 2015. The company secured third ... place in the “Best Registered Massage Therapist” category. ... community newspapers in Canada, The Vancouver Courier is ...
(Date:3/4/2015)... 2015 State officials have awarded $82,500 ... of Public Health at Georgia State University, to support ... by Georgia’s Division of Family and Children Services (DFCS) ... Call Center. , The 1-800-CHILDREN Helpline is a ... and referral services that promote the wellbeing of children ...
(Date:3/4/2015)... (PRWEB) March 04, 2015 The popular ... of their new L-Style Revolution™ Program. The customized program ... and women of all health and fitness levels to ... goals faster than traditional methods. , “We’re really proud ... customized plans based on award winning techniques to help ...
Breaking Medicine News(10 mins):Health News:FDAnews Announces: FDA’s New Inspection Approach: What Your Inspector Knows in Four Hours Webinar, March 24, 2015 2Health News:FDAnews Announces: FDA’s New Inspection Approach: What Your Inspector Knows in Four Hours Webinar, March 24, 2015 3Health News:FDAnews Announces: FDA’s New Inspection Approach: What Your Inspector Knows in Four Hours Webinar, March 24, 2015 4Health News:Per Wickstrom Offers Guide to Parents for Keeping Youth Sober 2Health News:Backs in Action Receives Two Awards in The Vancouver Courier Readers’ Choice Awards 2015 2Health News:State Funds Child Abuse Helpline Housed At Georgia State 2Health News:The Makers of Liporidex, The Popular Sports Nutrition Supplement Brand, Launches Its New L-Style Revolution™ Diet & Exercise Program That Promises Turbo Charged Results 2
... Manuel Uribe Garza, thought to be the world's fattest man, had weighed ... been able to shed in just over a year as much as ... ,Seven fully grown men in all, standing in a line. That ... said to have gone out of his body! No-one knows for sure ...
... Haven, Conn. Yale Cancer Center is proud to announce the ... WNPR Connecticut Public Radio. Beginning on National Cancer Survivors Day ... to 6:30 p.m. on Sunday evenings and feature the latest ... and Ken Miller, M.D. , ,Cancer Answers is ...
... killed six people and affected 32 in a tribal-dominated Orissa ... ,All the deaths took place in Koraput district. The victims ... ,Two people from the Paraja and Sirimunda village, ... May 20 and 21, while four more succumbed later, chief ...
... the brain could help treat people who are suffering ... responding to traditional treatment. ,Thomas Schlaepfer, professor ... Germany and associate professor of psychiatry and mental health ... and his team are examining the prospects of deep ...
... developing world to look for new initiatives and programmes targeting ... many nations in the African continent are hard pressed for ... ,Like elsewhere in the third world, visitors to Zambia ... of persons walking aimlessly along the roads, talking to themselves ...
... and Onyx Pharmaceuticals, Inc. today announced that Nexavar(R) ... with hepatocellular carcinoma (HCC), or primary liver ... were presented at the 43rd annual meeting of ... ,The international, Phase 3, placebo-controlled Sorafenib HCC ...
Cached Medicine News:Health News:Worlds Heaviest Man Loses Weight Thanks to Monitored Dieting 2Health News:Yale Cancer Center Answers: A New Weekly Radio Progam on WNPR 2Health News:Implanting Electrodes in the Brain Could Help Treat Severe Depression 2Health News:Zambia Trying Hard to Tackle Crisis in Mental Health Care 2Health News:Nexavar Significantly Extends Survival of Liver Cancer Patients 2
EZ-PSA is a one-step immunoassay for the rapid, qualitative determination of human Prostate Specific Antigen (PSA) in whole blood. The test is intended for professional use as an aid in the diagnosis...
Remote Control Vision Tester Can Administer Basic,Distance Vision Tests in Less Than 2 Minutes....
... Increase profitability ... time with simple ... be administered by ... in,less than 5 ...
Vectograms are the standard for vision training. They are available in fixed or variable,styles to accommodate unlimited base-in and base-out training. Each vectogram,includes one pair,of standard 3-...
Medicine Products: